Imperial College London
Portrait Picture

DrSumeetHindocha

Faculty of Medicine, Department of Surgery & Cancer

Honorary Clinical Research Fellow
 
 
 
//

Contact

 

s.hindocha19 Website

 
 
//

Location

 

//

Summary

 

Publications

Citation

BibTex format

@article{Hindocha:2021:10.3389/fmed.2021.764563,
author = {Hindocha, S and Campbell, D and Ahmed, M and Giorgakoudi, K and Sharma, B and Yosaf, N and Molyneaux, P and Hunter, B and Kalsi, H and Cui, W and Davidson, M and Bhosle, J and Minchom, A and Locke, I and McDonald, F and O'Brien, M and Popat, S and Lee, R},
doi = {10.3389/fmed.2021.764563},
journal = {Frontiers in Medicine},
pages = {1--10},
title = {Immune checkpoint inhibitor and radiotherapy-related pneumonitis: an informatics approach to determine real-world incidence, severity, management & resource implications},
url = {http://dx.doi.org/10.3389/fmed.2021.764563},
volume = {8},
year = {2021}
}
Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Pneumonitis is a well-described, potentially life-threatening adverse effect of immune checkpoint inhibitors (ICI) and thoracic radiotherapy. It can require additional investigations, treatment, and interruption of cancer therapy. It is important for clinicians to have an awareness of its incidence and severity, however real-world data are lacking and do not always correlate with findings from clinical trials. Similarly, there is a dearth of information on cost impact of symptomatic pneumonitis. Informatics approaches are increasingly being applied to healthcare data for their ability to identify specific patient cohorts efficiently, at scale. We developed a Structured Query Language (SQL)-based informatics algorithm which we applied to CT report text to identify cases of ICI and radiotherapy pneumonitis between 1/1/2015 and 31/12/2020. Further data on severity, investigations, medical management were also acquired from the electronic health record. We identified 248 cases of pneumonitis attributable to ICI and/or radiotherapy, of which 139 were symptomatic with CTCAE severity grade 2 or more. The grade ≥2 ICI pneumonitis incidence in our cohort is 5.43%, greater than the all-grade 1.3–2.7% incidence reported in the literature. Time to onset of ICI pneumonitis was also longer in our cohort (mean 4.5 months, range 4 days-21 months), compared to the median 2.7 months (range 9 days−19.2 months) described in the literature. The estimated average healthcare cost of symptomatic pneumonitis is £3932.33 per patient. In this study we use an informatics approach to present new real-world data on the incidence, severity, management, and resource burden of ICI and radiotherapy pneumonitis. To our knowledge, this is the first study to look at real-world incidence and healthcare resource utilisation at the per-patient level in a UK cancer hospital. Improved management of pneumonitis may facilitate prompt continuation of cancer therapy, and improved outcomes f
AU  - Hindocha,S
AU  - Campbell,D
AU  - Ahmed,M
AU  - Giorgakoudi,K
AU  - Sharma,B
AU  - Yosaf,N
AU  - Molyneaux,P
AU  - Hunter,B
AU  - Kalsi,H
AU  - Cui,W
AU  - Davidson,M
AU  - Bhosle,J
AU  - Minchom,A
AU  - Locke,I
AU  - McDonald,F
AU  - O'Brien,M
AU  - Popat,S
AU  - Lee,R
DO  - 10.3389/fmed.2021.764563
EP  - 10
PY  - 2021///
SN  - 2296-858X
SP  - 1
TI  - Immune checkpoint inhibitor and radiotherapy-related pneumonitis: an informatics approach to determine real-world incidence, severity, management & resource implications
T2  - Frontiers in Medicine
UR  - http://dx.doi.org/10.3389/fmed.2021.764563
UR  - https://www.frontiersin.org/articles/10.3389/fmed.2021.764563/full
UR  - http://hdl.handle.net/10044/1/92612
VL  - 8
ER  -
Download